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Inborn errors of mitochondrial β-oxidation cause ectopic fat accumulation, particularly in the liver. Fatty liver is associated with insulin
resistance and predisposes to hepatic fibrosis. The factors underlying the pathophysiological consequences of hepatic fat accumulation have
remained poorly defined. Gene expression profiling in a model of acute fatty liver disease induced by blocking long-chain fatty acid β-oxidation
was performed to study the early effects of steatosis on the transcriptome. Tetradecylglycidic acid (TDGA) was used to irreversibly inhibit
carnitine palmitoyltransferase 1, a key enzyme in the control of mitochondrial β-oxidation. TDGA treatment induced massive microvesicular
hepatic steatosis within a 12-h time frame in male C57BL6/J mice. Increased hepatic long-chain acyl-CoA content, particularly of C16:0, C16:1
and C18:1, was associated with profound effects on the transcriptome as revealed by unbiased gene expression profiling and quantitative real-time
PCR. The results indicate drastic changes in the expression of genes encoding proteins involved in lipid, carbohydrate, and amino acid
metabolism. Pathway analysis identified transcription factors and coregulators such as hepatocyte nuclear factor 4 (HNF4), peroxisome
proliferator-activated receptor-α (PPAR-α), and PPAR gamma coactivator 1α (PGC-1α ) as key players in these metabolic adaptations. Apoptotic
and profibrotic responses were also affected. Surprisingly, a strong reduction in the expression of genes involved in hepatic bile salt metabolism
and transport was observed. Therefore, this transcriptome analysis opens new avenues for research.
© 2007 Elsevier Inc. All rights reserved.Keywords: Transcriptome; Transcriptomics; Long-chain fatty acids; Steatosis; Bile salt metabolism; Peroxisome proliferator-activated receptor; Carnitine
palmitoyltransferase; EtomoxirIntroduction
Defects in mitochondrial β-oxidation are associated with
hypoketotic hypoglycemia and the accumulation of fat in organs
such as the heart and the liver. Ectopic fat accumulation has
been implicated in the development of metabolic derangements
occurring in insulin-resistant states. The mechanisms under-
lying this relationship have only been partly revealed. It is⁎ Corresponding author. Fax: +31 50 3611746.
E-mail address: f.kuipers@med.umcg.nl (F. Kuipers).
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doi:10.1016/j.ygeno.2007.08.004known that in the liver nuclear receptors like peroxisome
proliferator-activated receptor-α (PPAR-α) and hepatocyte
nuclear factor 4 (HNF4) play pivotal roles in the genomic
responses on accumulated intermediates of LCFA(long-chain
fatty acids) metabolism [1–5]. The use of transcriptome
analysis (“transcriptomics”) should reestablish their roles,
even though transcriptome analysis is limited to the measure-
ment of steady-state levels of mRNA and the mRNA levels of
these receptors themselves could remain unchanged. Next to
these established pathways, new avenues of research can be
opened with unbiased gene expression profiling as a first step
toward addressing potential metabolic implications that were
previously unknown.
Fig. 1. Long-chain acyl-CoA profiles of livers from control and TDGA-treated
mice.Tandem mass spectrometry after HPLC prepurification was used to obtain
the LCAC profiles of livers from control (white bars, n=5) and TDGA-treated
(black bars, n=6) mice. Asterisks denote significant (Pb0.05) differences
between specific chain-length LCAC species. All values represent means±SD
for the number of animals indicated. Statistical analysis was carried out by
applying the Mann Whitney U test.
681F.R. van der Leij et al. / Genomics 90 (2007) 680–689Carnitine palmitoyltransferase I (CPT-I) is a key enzyme in
the regulation of the mitochondrial β-oxidation of long-chain
fatty acids [6,7]. The enzyme resides in the outer mitochon-
drial membrane [8] and is naturally inhibited by malonyl-CoA
[6], the product of the first reaction in de novo fatty acid
biosynthesis. The consequences of CPT-I inhibition include
the accumulation of LCFA derivatives such as triglycerides
(TGs), which is considered one of the earliest events in the
development of insulin resistance [5,9]. Control of hepatic
fatty acid metabolism, which is strongly interrelated with
hepatic carbohydrate metabolism, plays a central role in the
maintenance of whole body energy metabolism, particularly
during fasting [1,10]. Processes involved in fatty acid
metabolism are subject to stringent (post)-transcriptional
control. Early events that occur during the development of
nonalcoholic fatty liver disease (NAFLD), a condition that
generally predisposes to nonalcoholic steatohepatitis (NASH),
are of crucial importance since at this stage deleterious con-
sequences may still be reversible. Whereas “chronic” NASH
has been studied at various levels, including the application
of microarray analysis [11], information on acute effects of
hepatic lipid accumulation on hepatic gene expression is
limited. Recent work has yielded considerable insight into the
molecular mechanisms underlying the hepatic gene responses
induced by fasting, a condition associated with “physiological”
and reversible hepatic steatosis due to release of excess fatty
acids from adipose tissue [12],which appears to be governed
largely by PPAR-α [1–3].
However, the genome-wide consequences of a rise in
cytosolic LCFA and long-chain acyl-CoA (LCAC) as such are
not known. Therefore, we performed gene expression profiling
in a model of acute hepatic steatosis induced by blocking LCFA
β-oxidation to gain insight at the level of the transcriptome.
Tetradecylglycidic acid (TDGA) was applied in mice to
irreversibly inhibit CPT1 [7]. The model is characterized by
massive microvesicular hepatic steatosis within a 12-h time
frame, accompanied by the accumulation of TGs and
nonesterified fatty acids (NEFA) in plasma. [13]. Under these
conditions, gluconeogenesis was found to be only slightly
suppressed while hepatic glucose production remained unaf-
fected. TDGA-induced inhibition of FA oxidation in perfused
rat livers decreased the hepatic ATP/ADP ratio by about 20%
[14]. These data indicate that TDGA treatment does not induce
an acute energy crisis in hepatocytes.
We aimed to quantify the degree of LCAC accumulation
and to relate this to hepatic gene expression profiles in
mice. Unbiased profiling was performed through the applica-
tion of oligomer microarrays, whereas the expression of a
selected number of genes was measured by quantitative real-
time PCR. This acute model of hepatic steatosis revealed
concerted changes in the expression of genes of major
pathways in energy metabolism and hepatic cell cycle control
and emphasizes a role for transcription factors and coregu-
lators, such as HNF4, PPAR-α, and PGC-1α as well as of
IGF-1. Surprisingly, the results show strong inhibition of
several genes involved in hepatic bile acid metabolism and
transport.Results and discussion
Long-chain acyl-CoA accumulation in the livers of
TDGA-treated mice
Quantification of hepatic TG content (+560%) and oil red O
staining for neutral lipids confirmed the massive hepatic
steatosis in TDGA-treated mice [13]. As expected from the
site of action of TDGA, LC-acyl-CoA esters accumulated in the
livers of TDGA-treated mice (Fig. 1). LCAC profiling revealed
significantly (Pb0.05) higher levels of myristoyl- (C14:0),
palmitoyl (C16:0), palmitoleoyl- (C16:1), and oleoyl- (C18:1)
CoA esters in livers of TDGA-treated mice. The accumulation
of oleoyl-CoAwas the most prominent. A predominance of 18:1
acyl species was also found in the VLDL-triglyceride profile
obtained in the same model [13]. The total hepatic LCAC
increase was less than 2-fold between control (123±48 nmol
LCAC/g liver) and TDGA-treated mice (212±48 nmol LCAC/g
liver) (P=0.006). This moderate increase probably is a con-
sequence of rapid incorporation of LCAC into triglycerides
(control, 19.9±8.3 μmol/g liver, vs TDGA, 112.4±25.2 μmol/g
liver). As described [13], the TDGA-treated mice were hypo-
glycemic compared to controls during the course of the
experiment, probably reflecting the use of glucose as energy
source instead of fatty acids.
Global analysis of hepatic gene expression
For microarray analysis, we used two linear statistical
approaches which, when combined, revealed a robust set of
differentially expressed genes that was partly confirmed by real-
time PCR analysis (see below). Principal component (PC)
analysis on the complete data set showed that the second PC
was informative for the hybridizations [15] of test versus control
samples (Fig. 2, loop1 and loop 2) whereas this second
component did not apply to the two self–self experiments.
Employing a threshold for the standard deviation exceeding two
(SDN2) yielded 403 genes to be differentially expressed
according to PC analysis.
Fig. 2. Double loop model used in the microarray design. Two loops of
hybridized cDNA from livers of control (C) and TDGA-treated (T) mice were
applied, using 12 samples in total. The self–self hybridizations served as control
experiments. Arrows indicate the direction of a hybridization: solid arrows
symbolize green and dotted arrows red labeling of the cDNA.
Table 1
Differentially expressed genes for transcription factors
Symbol GenBank
accession
Full gene name Fold change
MA PCR
Cbfa2t3h NM_009824 Core-binding factor, runt domain,
alpha subunit 2, translocated to,
3 homolog
3.66
Bcl11a NM_016707 B-cell CLL/lymphoma 11A
(zinc finger protein)
2.84
Ppargc1a NM_008904 Peroxisome
proliferative-activated receptor,
gamma, coactivator 1 alpha
1.73 2.43
Mbd1 NM_013594 Methyl-CpG binding domain
protein 1
2.1
Peg3 NM_008817 Paternally expressed 3 1.94
682 F.R. van der Leij et al. / Genomics 90 (2007) 680–689The second statistical approach made use of array analysis
according to the BRB software package from NIH. Raw data
were filtered for reliability (allowing maximally 3 out of the 12
measurements per gene to be flagged or missing), which yielded
3226 genes. Of these genes, 411 were differentially expressed
according to the criterion Pb0.001.
The two sets of genes thus obtained had 232 differentially
expressed genes in common, 52 of which were more than 2-fold
higher expressed and 29 were more than 2-fold lower expressed
in TDGA-treated animals compared to control animals. The full
list of differentially expressed genes is added as Supplemental
Table 2.
Real-time PCR
We measured the hepatic expression levels of 44 genes
selected on the basis of reported function, by quantitative real-
time PCR. Supplemental Table 1 lists all previously unpub-Fig. 3. Correlation of expression data from microarray and real-time PCR
analysis. The “fold change” differences in expression levels as determined
by microarray hybridizations (x-axis) and real-time PCR (y-axis) are plotted
to visualize the quantitative correlation (n=17). These 17 genes are all in
the set of 232 as obtained by microarray and that were measured by real-
time PCR.lished primers and probes used for real-time PCR. A list of the
“fold change” values of the 44 genes determined by real-time
PCR can be found in Supplemental Table 3. From the total of
232 differentially expressed genes identified by microarray as
described above, 17 were tested for their expression level by
real-time PCR. With the exception of one (the Pygl gene
encoding glycogen phosphorylase), differential expression of
all these genes was confirmed by real-time PCR. The direction
of change and the “fold change” of these genes was comparable
between microarray and real-time PCR (Fig. 3).
In addition, we determined the expression of several genes
that did not show up in the microarray experiments. These genes
were not represented on the chip (e.g., Acaca; Cpt1b), not in the
filtered list of 3226 genes (e.g., Acacb), or showed P values
higher than 0.001 in the microarray analysis (e.g., Cpt1a; Pdk4;
Cyp8b1; Cyp7a1). However, these genes encode proteins
that are considered of importance in hepatic lipid, carbohydrate,
and bile acid metabolism and are intensively studied in our
laboratory.Nr1d1 NM_145434 Nuclear receptor subfamily 1,
group D, member 1 (Reverb-a)
1.81
Sp3 AF062567 trans-acting transcription
factor 3
1.8
Nr1h3 AF085745 Nuclear receptor subfamily 1,
group H, member 3 (LXR alpha)
−1.24
Esr1 NM_007956 Estrogen receptor 1 (alpha) −1.41
Nr1h4 NM_009108 Nuclear receptor subfamily 1,
group H, member 4 (FXR)
−1.42 −1.52
Xbp1 NM_013842 X-box binding protein 1 −1.45
Isgf3g NM_008394 Interferon-dependent positive
acting transcription factor 3
gamma
−1.94
Stat2 NM_019963 Signal transducer and activator
of transcription 2
−1.99
Pou3f2 NM_008899 POU domain, class 3,
transcription factor 2
−2.13
Zfp35 NM_011755 Zinc finger protein 35 −2.29
Bcl3 AF067774 B-cell leukemia/lymphoma 3 −2.58
Srebf1 NM_011480 Sterol regulatory element binding
factor 1
−2.62
Mlxipl NM_021455 Williams-Beuren syndrome
chromosome region 14
homolog (ChRebp)
−1.55 −3.44
Nr0b2 L76567 Nuclear receptor subfamily 0,
group B, member 2 (SHP)
−4.49
Table 3
Differentially expressed genes for peroxisomal proteins
Symbol GenBank
accession
Full gene name Fold change
MA PCR
Ehhadh AJ011864 Enoyl-coenzyme A,
hydratase/3-hydroxyacyl coenzyme A
dehydrogenase
6.71
Crat NM_007760 Sarnitine acetyltransferase 2.19 3.00
Abcd3 NM_008991 ATP-binding cassette, sub-family D
(ALD), member 3
1.98
Peci NM_011868 Peroxisomal delta3,
delta2-enoyl-coenzyme A isomerase
1.77
Pex19 Y09046 Peroxisomal farnesylated protein 1.64
683F.R. van der Leij et al. / Genomics 90 (2007) 680–689The set of 232 genes obtained from microarray selection
was increased by the differentially expressed genes according
to real-time PCR to 250 genes. This set was used to create
network representations. Global gene ontology analysis on the
unbiased group of 232 genes indicated that most of the
affected genes related to primary metabolic processes (Supple-
mental Table 4). For further interpretation we divided the
differentially expressed genes into ontologically related subsets
(Tables 1−6). The major subsets of differentially expressed
genes are related to mitochondrial (Table 2) and peroxisomal
(Table 3) functions including genes involved in lipid
metabolism (Fig. 4), carbohydrate metabolism (Table 4),Table 2
Differentially expressed genes for mitochondrial proteins
Symbol GenBank
accession
Full gene name Fold change
MA PCR
Pdk4 NM_053551 Pyruvate dehydrogenase kinase,
isoenzyme 4
29.11
Cpt1b NM_013200 Carnitine palmitoyltransferase 1b 7.29
Ucp3 NM_009464 Uncoupling protein 3, mitochondrial 2.5 5.01
Aass NM_013930 Aminoadipate-semialdehyde
synthase
3.6
Crat NM_007760 Carnitine acetyltransferase 2.19 3.00
Gpd2 NM_010274 Glycerol phosphate
dehydrogenase 2, mitochondrial
2.38
Grpel2 AF041060 GrpE-like 2, mitochondrial 2.17
Acadm NM_007382 Acetyl-coenzyme A dehydrogenase,
medium chain
1.91
Acadl NM_007381 Acetyl-coenzyme A dehydrogenase,
long-chain
1.7
Gpam NM_008149 Glycerol-3-phosphate
acyltransferase, mitochondrial
1.88 1.69
Cpt2 NM_009949 Carnitine palmitoyltransferase 2 1.67
Fh1 U72679 Fumarate hydratase 1 1.66
Ucp2 NM_011671 Uncoupling protein 2, mitochondrial 1.78 1.64
Slc25a20 NM_053965 Solute carrier family 25
(carnitine/acylcarnitine translocase),
member 20
1.62
Slc25a15 NM_011017 Solute carrier family 25
(mitochondrial carrier ornithine
transporter), member 15
1.58
Amacr NM_008537 Alpha-methylacyl-CoA racemase 1.55
Cpt1a NM_013495 Carnitine palmitoyltransferase
1a, liver
1.5
Glud1 NM_008133 Glutamate dehydrogenase 1 −1.35
Sh3bp5 NM_011894 SH3-domain binding protein 5
(BTK-associated)
−1.49
Nit2 AF284573 Nitrilase family, member 2 −1.51
Cabc1 AJ278735 Chaperone, ABC1 activity of bc1
complex like (S. pombe)
−1.52
Shmt1 NM_009171 Serine hydroxymethyl
transferase 1 (soluble)
−1.55
Sqrdl NM_021507 Sulfide quinone reductase-like
(yeast)
−1.65
Pemt NM_008819 Phosphatidylethanolamine
N-methyltransferase
−1.36 −1.74
Hebp1 NM_013546 Heme binding protein 1 −1.8
Hsb3b1 NM_008293 Hydroxy-delta-5-steroid
dehydrogenase, 3-beta- and
steroid delta-isomerase 1
−2.02
Keg1 AB028071 Kidney expressed gene 1 −4.31
Gck L38990 Glucokinase −4.04 −4.48
Amacr NM_008537 Alpha-methylacyl-CoA racemase 1.55
Pecr AF232011 Peroxisomal trans-2-enoyl-CoA
reductase
−1.49
Hao1 NM_010403 Hydroxyacid oxidase 1, liver −1.54
Pipox NM_008952 Pipecolic acid oxidase −1.64amino acid metabolism (Table 5), bile acid metabolism (Fig.
5), and apoptosis (Table 6). Transcription factors, central
players in these processes, are listed in (Table 1). Surprisingly,
no distinct subset of genes related to inflammation appeared to
be induced in this acute model of hepatic steatosis. Likewise,
no indications for macrophage infiltrations were evident from
microscopical examination of liver sections. This is in contrast
to high-fat diet-induced hepatic steatosis in mice, in whichTable 4
Differentially expressed genes for enzymes and transporters in carbohydrate
metabolism
Symbol GenBank
accession
Full gene name Fold change
MA PCR
Pkm2 NM_011099 Pyruvate kinase, muscle 5.18
Ppargc1a NM_008904 Peroxisome proliferative-activated
receptor, gamma, coactivator alpha
1.73 2.43
Gpd2 NM_010274 Glycerol phosphate dehydrogenase 2,
mitochondrial
2.38
Gfpt2 NM_013529 Glutamine fructose-6-phosphate
transaminase 2
2.34
Aldoa NM_007438 Aldolase 1, A isoform, pseudogene 2 2.29
Gys2 NM_145572 Glycogen synthase 2 1.8
G6pc NM_008061 Glucose 6-phosphatase, catalytic 1.77 1.77
Fh1 U72679 Fumarate hydratase 1 1.66
Hyal1 NM_008317 Hyaluronidase 1 −1.25
Slc37a4 NM_008063 Solute carrier family 37
(glycerol-6-phosphate transporter),
member 4
−1.52
Gne NM_015828 Glucosamine −1.55
Slc3a1 NM_009205 Solute carrier family 3, member 1 −1.63
Khk NM_008439 Ketohexokinase −1.66
PygI AF288783 Liver glycogen phosphorylase −1.69
Slco1b2 NM_020495 Solute carrier organic anion
transporter family, member 1b2
(oatp2)
−2.26
B3galt1 NM_020283 UDP-Gal:betaGlcNAc beta
1,3-galactosyltransferase,
polypeptide 1
−4.41
Pklr NM_013631 Pyruvate kinase liver and red
blood cell
−4.43
Gck L38990 Glucokinase −4.04 −4.48
Table 5
Differentially expressed genes involved in amino acid metabolism a
Symbol GenBank
accession
Full gene name Fold change
MA PCR
Ehhadh AJ011864 Enoyl-coenzyme A,
hydratase/3-hydroxyacyl
coenzyme A dehydrogenase
6.71
Gfpt2 NM_013529 Glutamine fructose-6-phosphate
transaminase 2
2.36
Crat NM_007760 Carnitine acetyltransferase 2.19 3.00
Aldh3a2 NM_007437 Aldehyde dehydrogenase family 3,
subfamily A2
1.94
Acadm NM_007382 Acetyl-coenzyme A dehydrogenase,
medium chain
1.91
Adh7 NM_009626 Alcohol dehydrogenase 7 (class IV),
mu or sigma polypeptide
1.72
Glud1 NM_008133 Glutamate dehydrogenase −1.35
Pemt NM_008819 Phosphatidylethanolamine
N-methyltransferase
−1.36 −1.75
Akr1e1 NM_018859 Aldo-keto reductase family 1,
member E1
−1.41
Akr1c12 NM_013777 Aldo-keto reductase family 1,
member C12
−1.44
Shmt1 NM_009171 Serine hydroxymethyl transferase 1
(soluble)
−1.55
Gclc U85498 Glutamate-cysteine ligase, catalytic
subunit
−1.59
Pipox NM_008952 Pipecolic acid oxidase −1.64
Gclm NM_008129 Glutamate-cysteine ligase, modifier
subunit
−1.82
Got1 NM_010324 Glutamate oxaloacetate transaminase
1, soluble
−1.86
Comt NM_007744 Catechol-O-methyltransferase −1.9
Adh1 NM_007409 Alcohol dehydrogenase 1 (class I) −2.13
Cyp2a4 NM_009997 Cytochrome P450, family 2,
subfamily a, polypeptide 4
−2.51
a Note that some of these gene products are better known for their functions in
other pathways (like fatty acid metabolism) but also act in steps of amino acid
metabolic pathways.
Table 6
Differentially expressed apoptotic and antiapoptotic genes
Symbol GenBank
accession
Full gene name Fold change
MA PCR
Cidec M61737 Fat-specific gene 27 5.68
Tnfrsf12a NM_013749 Tumor necrosis factor receptor
superfamily, member 12a
4.31
Cdkn1a NM_007669 Cyclin-dependent kinase inhibitor
1A (P21)
2.53
Sgk NM_011361 Serum/glucocorticoid regulated
kinase
1.77
Btg2 NM_007570 B-cell translocation gene 2,
antiproliferative
1.68
Gadd45g NM_011817 Growth arrest and
DNA-damage-inducible 45 gamma
1.56
Igf1 NM_010512 Insulin-like growth factor 1 −1.46
Hsp90ab1 NM_008302 Heat shock protein 1, beta −1.48
Mcl1 NM_008562 Myeloid cell leukemia sequence 1 −1.48
Cflar NM_009805 CASP8 and FADD-like apoptosis
regulator
−1.62
684 F.R. van der Leij et al. / Genomics 90 (2007) 680–689rapid macrophage infiltration was recently reported to preced
fat accumulation [16].
Insulin-sensitive genes are differentially expressed at the
transcriptional level
Since hepatic insulin sensitivity appeared to be unaffected at
the level of VLDL formation and phosphatidylinositol-3 kinase
phosphorylation on TDGA treatment [13], we initially focused
our attention on metabolic pathways that can be modulated by
insulin. Several genes encoding proteins affected by insulin
were found to be differentially expressed on TDGA treatment.
The gene encoding SREBP-1c (sterol regulatory element
binding protein-1c) was lower expressed in the livers of
TDGA-treated mice compared to control (2.6-fold), whereas the
Pdk4 gene for pyruvate dehydrogenase kinase 4 and Ppargc1a
(for PPAR gamma coactivator 1α; PGC-1α) were higher
expressed (29.1- and 2.4-fold, respectively). These genes are all
known to be highly insulin responsive: their strong regulation is
compatible with a lowering of plasma insulin levels due to
hypoglycemia on β-oxidation inhibition. Downstream targets ofthese proteins were switched off, e.g., Gck, Pklr, and Pkm2
encoding glucokinase and liver- and muscle-type pyruvate
kinase, respectively. Thus, genes involved in glycolysis were
switched off and the key gene enabling inhibition of pyruvate
oxidation (Pdk4) was switched on, probably reflecting
responses aimed at sparing of glucose. In the condition of
suppressed β-oxidation the body entirely depends on available
glucose because neither ketone bodies nor energy needed for
gluconeogenesis are being generated. The higher expression of
Ppargc1a also known to occur during the fasting response could
be a potential signal to increase gluconeogenesis [17,18]. G6pc
(encoding the catalytic unit of glucose 6-phosphatase) was
indeed higher expressed on treatment but expression of G6pt
(Slc37a4), encoding the transporter subunit of glucose 6-
phosphatase, was reduced and that of Pck1 (Pepck for
phosphoenol pyruvate carboxylase kinase) remained unaf-
fected. The indifferent and low expression of the genes Acaca
for acetyl-CoA carboxylase 1 and Fasn for fatty acid synthase,
both involved in lipogenesis, is also compatible with low insulin
levels, leading to suppressed SREBP-1c expression. These
genes were already expressed at such low levels in the fasted
control state that further down-regulation was not anticipated.
Repression of the Mlxipl gene (3.45 times down) for the
glucose-sensing transcription factor ChREBP (carbohydrate
response element binding protein) is fully in line with impaired
lipogenic gene transcription [19,20].
Genes involved in fatty acid oxidation are induced by a
feedback mechanism
The massive changes in expression of genes encoding
mitochondrial proteins may be part of a PGC-1α-mediated
response. PGC-1α is the central orchestrating coactivator for
mitochondriogenesis. Since mitochondria and peroxisomes are
primary sites for oxidative processes it was not surprising to
find many genes of fatty acid oxidation to be up-regulated.
Fig. 4. Partial network representation. Several interconnected pathways were visualized by the use of the program Pathway Assist and Pathway Architect (Stratagene).
A part of these networks is shown here, with black boxes for genes that are higher expressed, and white boxes for genes that were lower expressed in the livers of
TDGA-treated mice. The gray box symbolizes unchanged expression of Ppara. The other gene symbols are explained in the text and tables.
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peroxisome proliferator-activated receptor α (PPAR-α, which
is coactivated by PGC-1α). Since TDGA itself may act as a
PPAR-α ligand [21], part of these effects may be a direct
consequence of the treatment. These responses are characterized
by overexpression of Cpt1a and Cpt1b, as well as other genes
involved in β-oxidation (Cpt2; Acadl; Acadm) and LCFA
partitioning (Slc25a20; Ucp2; Ucp3). The 5-fold increase in
expression of the latter gene is in line with its proposed role as a
mitochondrial fatty acid efflux protein [22]. Besides these
feedback mechanisms, feed forward mechanisms may be
involved as well. The response seems to anticipate a larger
acetyl-CoA pool: the Crat gene encoding the buffering enzyme
carnitine acetyltransferase was 3-fold higher expressed in theFig. 5. Flawed expression of genes involved in bile salt metabolism. The liver
cell with the bile canaliculus is schematically drawn, representing three major
transporters in bile formation, i.e., the organic anion transporter 2 (Oatp2), Na+/
taurocholate cotransporter (Ntcp), bile salt exchange protein (Bsep), as well as
two cytochrome P450 enzymes (Cyp7a and Cyp8b) and the trancription factors
peroxisome proliferator-activated receptor-α (Ppar-α), liver X receptor (Lxr),
short heterodimer partner (Shp), farnasoid X receptor (Fxr), and liver receptor
homolog 1 (Lrh1). Positive actions are depicted by arrows, negative by blunted
bars. Thick arrows indicate the flow of bile salts. Expression levels are indicated
as “fold change” compared to control, as determined by real-time PCR. All
changes shown were statistically significant according to the Mann Whitney U
test, except Ppar-α.treated group. Carnitine acetyltransferase is important for both
mitochondrial and peroxisomal acetyl-CoA and acetylcarnitine
homeostasis [7]. Cellular carnitine uptake could be facilitated
by the strong induction (almost 4-fold difference) of the gene
encoding the plasma membrane carnitine transporter OCTN2.
Many genes involved in the intracellular transport and the
β-oxidation of LCFA are PPAR-α targets. Therefore, it is not
surprising that PPAR-α is centrally positioned in a global
pathway analysis such as depicted in Fig. 4.
Surprisingly, the Acacb gene for acetyl-CoA carboxylase 2
(ACC2) was 1.72-fold higher expressed in treated mice. This is
remarkable since ACC2 is the isoform primary responsible for
inhibition of CPT1 by malonyl-CoA in the liver [23]. Therefore,
it was unexpected that this gene would become up-regulated in
a situation of artificial inhibition of CPT1. The regulation of
transcription of Acacb has not been elucidated [24] and our
findings provide clues for further investigations.
In addition to PPAR-α as intracellular sensor of LCFA, it has
been indicated that hepatocyte nuclear factor 4 is important in
the concerted regulation of genes encoding the LCFA metabolic
machinery. HNF4 is considered a master switch in the control of
metabolic genes [4,5] and its importance in the development of
diabetes is well-recognized [25]. As depicted in Supplemental
Tables 2 and 3, 59 out of the 250 differentially expressed genes
were associated with HNF4, accounting for 24% of total,
indicating a major role of this nuclear receptor in the responses
observed.
Circumstantial evidence suggests signaling by LCFA rather
than LCAC
Blocking β-oxidation by TDGA results in hepatic accumu-
lation of LCAC (Fig. 1). This accumulation was moderate
compared to the profound effects on triglyceride accumulation.
We found that the two genes encoding acyl-CoA synthases
(Acsl1 and Slc27a4) were more highly expressed in TDGA-
treated mice than in controls (2.1- and 1.9 –fold, respectively).
Both the Acsl1 gene [26] and the Slc27a4 gene for FATP4 [27]
encode proteins that possess acyl-CoA synthetase activity. The
latter contains a distinct peroxisome proliferator response
element in its promoter [28]. The enzyme activities enable the
686 F.R. van der Leij et al. / Genomics 90 (2007) 680–689cell to covert LCFAs into their CoA esters which is needed for
further partitioning.
When β-oxidation is blocked, LCFA are largely partitioned
toward TG. The finding that the expression of two independent
genes for acyl-CoA synthetases were induced provides
circumstantial evidence, suggesting that the major effectors of
the molecular cascades are the free LCFA rather than their CoA
derivatives. Although acyl-CoAs are assumed to be important in
the development of insulin resistance, the natural ligands of the
nuclear receptors of the PPAR family and HNF4 are the free
fatty acids rather than their CoA derivatives [3–5]. LCFA and
LCAC accumulation can be detrimental due to the amphiphilic
character of these molecules and, therefore, liver cells respond
promptly by inducing the machinery to lower their concentra-
tions. In addition, in nonliver tissue “futile cycling” has been
proposed as an ATP-consuming mechanism through the action
of fatty acid ligases and cytosolic thioesterase 1 (CTE1) [29].
Indeed, the gene for CTE1 was up-regulated 5-fold, suggesting
that futile cycling is facilitated to occur in liver also. Alter-
natively, the hypoglycemia could be responsible for mobiliza-
tion of fat resulting in high LCFA and elevated acyl-CoA
synthase expression.
Triglyceride formation and proposed partial partitioning into
VLDL
In the model studied, activation of LCFA could not be
followed by β-oxidation and therefore the formation of TG in
liver cells provided an immediate solution for avoiding
intracellular LCFA and LCAC accumulation. Indeed, the
Dgat1 and Gpam genes that encode enzymes required for TG
formation were induced on TDGA treatment, allowing the
partitioning of LCAC into TG. Dgat2 was lower expressed on
the treatment, implying that the Dgat1 over Dgat2 ratio was
increased. We reason that, despite the on-site accumulation of
TG, a part of the TG is further partitioned into VLDL. As shown
by Grefhorst et al. [13], total VLDL-TG production was not
affected on TDGA treatment but analysis of particle composi-
tion revealed an enrichment with C18:1 acyl species coinciding
with the composition of hepatic TG. Therefore, part of the
accumulated TG must have been incorporated into nascent
VLDL particles. Apob (1.25-fold up) is well known for its
decisive role in VLDL formation by hepatocytes; yet, control is
mainly exerted at posttranscriptional level [30,31]. The lower
expression of Pemt is intriguing in this respect, since the Pemt
gene product (phosphatidylethanolamine methyltransferase) is
needed for the secretion of VLDL-apoB [32]. Interestingly,
PEMT deficiency has recently been reported to aggravate
hepatic steatosis in mouse models [33].
Bile salt metabolism is massively affected on the blocking of
β-oxidation
An unexpected finding was the massive shift in expression
of genes involved in bile salt metabolism and transport (Figs. 4
and 5). The Cyp7a1 gene, encoding the rate-controlling enzyme
in bile salts biosynthesis, was very strongly suppressed (21.5-fold) while Cyp8b1, which determines the cholate/chenodeox-
ycholate ratio, was 1.75-fold higher expressed. The transcrip-
tional network including SHP (short heterodimer partner
encoded by Nr0b2), LXR (liver X receptor encoded by
Nr1h3), and FXR (farnesoid X receptor encoded by Nr1h4)
as depicted in Figs. 4 and 5 may be involved in this regulation.
PPAR-α is probably of prominent importance in this respect, as
pharmacological PPAR-α activation leads to similar alterations
in Cyp7a1 and Cyp8b1 gene expression in rodent livers
[34,35].
It should be noted that the Ehhadh gene was drastically up-
regulated (6.7-fold higher in TDGA-treated mice). This gene is
of relevance for bile salt metabolism since its product enoyl-
CoA hydratase/CoA dehydrogenase, also known as L-bifunc-
tional protein, catalyzes the alternative pathway of peroxisomal
side-chain shortening. However, its up-regulation may be pri-
marily a consequence of PPAR-α-mediated gene transcription
and can be regarded as part of the orchestrated up-regulation
of the β-oxidation machinery rather than an increased need
for side-chain shortening of bile salts. These results highlight an
as yet unknown relationship between the transcription of
genes needed for bile salt synthesis (i.e., cholesterol catabo-
lism) and the accumulation of intermediates of fatty acid
metabolism.
Insulin-like growth factor and other central players show
reduced expression after blocking β-oxidation
For several pathways (Fig. 4), insulin-like growth factor 1
(IGF1) is a key regulatory protein. The gene encoding IGF1 was
1.46-fold underexpressed on TDGA treatment compared to
control levels. In our analysis on pathway interconnections,
IGF1 showed up as a primary site of regulation that results in
changes in gene expression of major pathways of relevance for
hepatic steatosis. A total of 10 genes known to be involved in
apoptosis and antiapoptotic response were differentially
expressed (Table 6). Two of the highly up-regulated genes are
known to induce cell death (the Cidec gene was 5.68-fold and
the Tnfsf12 gene was 4.31-fold higher expressed). In addition,
Cyp4a10 known as marker for lipid peroxidation and res-
ponsive to PPAR-α [36], was 2.27-fold higher expressed on
TDGA treatment. These responses are likely part of a process in
the acute phase of steatosis development in which the liver cells
have to find a new equilibrium between apoptotic and
antiapoptotic activities. This is not surprising, given the fact
that major consequences of blocking β-oxidation are related to
mitochondria (Table 2) which have a central role in apoptotic
cascades. Indeed, in a recent in vitro study employing liver
slices, it was shown that blocking of LCFA β-oxidation may
cause apoptosis, especially if the blockade is downstream of
CPT1 [37]. However, in our study no signs of apoptosis or
inflammation were observed, likely due to the short-term nature
of the experiment.
Other effects that relate to lower expression of IGF1, and
also of estrogen receptor1 (Erα, encoded by Esr) and epidermal
growth factor receptor (EGFR) (Fig. 4), are the genes that
control cell cycle (suppression of oncogenesis), as well as
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collagen formation). These are obviously responses that are of
relevance for the acute effects of hepatic steatosis and our data
(added as Supplemental tables) may provide new angles to
approach the molecular networks underlying these effects.
Comparison to other microarray studies
The number of studies applying high-throughput gene
expression profiling in NAFLD is limited. These were carried
out with livers from human subjects, which by definition
reflect a more chronic state of steatosis. Compared to these
studies, we observed a number of similarities. Apart from
genes involved in fatty acid and carbohydrate metabolism as
discussed above, we also encountered a large number of
genes involved in amino acid metabolism (Table 5). Profound
changes in energy metabolism are a plausible explanation for
this finding, since many of the enzymes in amino acid metabo-
lism are highly dependent on ATP and reducing equivalents.
Part of these responses may be ascribed to PPAR-α activation
[38].
Compared to the literature there are also important dif-
ferences in outcome. For instance, responses to prevent
oxygen damage and to induce scavenging were clear-cut in
the study by Sreekumar et al. [11] but appeared not (yet) of
relevance in our acute model. Another example refers to the
fact that out of the list of 232 differentially expressed genes
(Supplemental Table 2) we only found 3 genes encoding
constituents of the cytoskeleton and 4 for extracellular matrix
proteins whereas analysis of a large number of human subjects)
indicated an important role for extracellular matrix remodeling
[39,40].
Chiappini et al. [41] studied biopsies that did not show
histological features of inflammation and therefore may be
considered as intermediate acute phase samples. Indeed, in
terms of classification (mitochondrial metabolism, inflamma-
tion) their findings most closely resemble the data presented
here, although many detailed differences are apparent. The
difference in composition of gene sets present on the micro-
arrays may contribute to these differences.
Concluding remarks
It is important to note that it is not possible to discuss the
relevance and impact of all genes and clusters that were
differentially expressed in this study. Therefore, this initial
analysis is focused on pathways that provide insight in the
major responses that occur during the acute phase of steatosis
development. By the use of transcriptome analysis we
reestablished the roles of some important nuclear receptors,
even though the use of primary data was limited to (sets of)
genes that were differentially expressed without measuring gene
product activity. Through pathway analysis the subsequently
distilled information revealed important factors, even though
the mRNA levels of these receptors themselves sometimes
remained indifferent. Our results show also that gene expression
profiling can be used as a first step toward addressing pre-viously unknown implications, like altered expression of genes
involved in bile salt metabolism and transport.
Materials and methods
Animals and chemicals
Male wild-type C57BL/6J mice (Harlan, Horst, the Netherlands) were
housed and treated according to protocols approved by the Animal
Experiments Ethical Committee of the University of Groningen. The mice
were housed under 12-h light/12-h dark regime and were fed normal chow
(RMH-B, Hope Farms, Woerden, the Netherlands) and water ad libitum, until
experimentation. Tetradecylglycydic acid (TDGA), a kind gift from Dr. P.J.
Voshol (LUMC, Leiden, the Netherlands), was suspended at a concentration of
2.0 mg/ml in a solution consisting of 90 mg/ml bovine serum albumin in
saline.
Animal experiments
Mice received an i.p. injection with 30 mg TDGA per kg bodyweight (n=6)
or vehicle (n=6 unless stated otherwise). Food was withdrawn but mice still had
access to water. After 12 h, the mice were killed by cardiac puncture under
isoflurane anesthesia. The abdomen was opened and the liver was quickly
removed and immediately frozen in liquid nitrogen and stored.
Acyl-CoA profiling
Extraction of LCAC was performed in frozen liver tissue according to
Mangino et al. [42] with slight modifications. Hepatic LCAC content was
determined by tandem mass spectrometry after HPLC prepurification (HPLC-
MS-MS) (Perkin Elmer/Biosystems Sciex; and Applied Biosystems). Multiple
reaction monitoring was performed to measure the different long-chain acyl-
CoA thioesters. The transitions used were the doubly charged m/z precursor ion
of LCAC at Q1 and the m/z product ion of the adenine residue at Q3. Full
protocols of these procedures are available on request.
Microarrays
The microarrays used contained the complete mouse oligonucleotide library
version 1 (Sigma-Genosys/Compugen) printed in duplicate on UltraGAPS
slides (Corning, Reading, UK). The mouse oligonucleotide library version 1
consists of 7524 gene-specific 65-mer oligos representing 7445 genes from a
diverse range of functionalities. In addition, positive and negative controls were
represented on the arrays. These microarrays were obtained from the
Department of Anthropogenetics at the Radboud University, Nijmegen, the
Netherlands, and are known to provide robust data [43].
RNA isolation and purification
Total RNA was isolated from 30 mg liver tissue by the use of Tri-Reagent
(Sigma-Aldrich, Zwijndrecht, the Netherlands), according to the manufac-
turer's protocol. RNA was purified with a RNeasy min Elute Clean-up kit
(Qiagen, Venlo, the Netherlands) according to the manufacturer's protocol.
The integrity and concentration were determined on an Agilent Bioanalyser
2100 (Palo Alto, CA).
Probe construction, hybridization, and data acquisition
Labeling of cDNA molecules through incorporation of aminoallyl-labeled
nucleotides was performed according to a protocol described at http://pga.tigr.
org/sop/M004_1a.pdf. Briefly, for each RNA sample, first-strand amino-
modified cDNA was synthesized by oligo(dT)-primed reverse transcription
from 20 μg total RNA using Superscript II reverse transcriptase (Invitrogen,
Paisly, UK) in the provided buffer and in the presence of 0.5 mM dATP, dCTP,
dGTP, 0.3 mM dTTP, and 0.2 mM amino-allyl dUTP. After 16 h incubation at
42 °C the RT reaction was stopped and cDNAwas purified as described. Purified
688 F.R. van der Leij et al. / Genomics 90 (2007) 680–689cDNA was fluorescently labeled with Cy3 or Cy5 fluorophores (Amersham
Biosciences, Roosendaal, the Netherlands) as described previously [44].
Labeled cDNA was purified using Microcon YM-30 size-exclusion columns
(Millipore, Amsterdam, the Netherlands).
Each probe was put together by mixing the labeled cDNA reactions from the
appropriate samples together with 15 μg poly(dA) DNA (Qiagen, Hilden,
Germany) and 7.5 μg human Cot-1 DNA (Invitrogen). This probe was heated at
95 °C for 3 min, cooled to 52 °C, and mixed with an equal volume of preheated
(52 °C) hybridization buffer to a final concentration of 25% formamide, 5X SSC
(saline sodium citrate) and 0.1% SDS. All hybridizations were performed under
lifterslips (Erie Scientific, Portsmouth, UK) within hybridization chambers
(Telechem, Sunnyvale) in a waterbath at 52 °C for 40 h. After hybridization the
slides were washed, dried and scanned at 10 μm resolution in a GMS 428 laser
scanner (Affymetrix, Santa Clara, CA). Image intensity data for each array
feature was extracted by ImaGene 5.6 software (BioDiscoveries, Marina Del
Rey, CA).
Microarray analysis and computation
A double loop design (Fig. 2) was applied to the microarray hybridization
experiment to minimize the number of microarray slides and still include dye-
swap readings for all samples [45]. In addition, a self–self hybridization was
included for both the control and the treatment group to account for technical
variation in the experiments. Expression analysis was performed by principal
component analysis in SPSS (Chicago, IL) [15] and by gene expression
analysis in the BRB-ArrayTools software package (BRB ArrayTools developed
by Simon and Peng Lam. For this latter BRB ArrayTools analysis control spots
were removed and raw array data were normalized for each printtip separately.
Intensity data of oligomer spots considered as empty, bad, or negative were
removed from the file and spots with more than 25% missing data across the
experiment were not included in the analysis. Differentially expressed genes
among the two classes were identified using a random-variance t test, an
improvement over the standard separate t test as it permits sharing information
among genes about within-class variation without assuming that all genes have
the same variance [46]. Genes were considered statistically significant if their P
value was less then 0.001. The datasets were compiled by the use of
Genespring software. The most prominent gene ontologies were identified by
DRAGON [47], Gostat [48], and DAVID [49]. Network presentations were
created with Pathway Assist and Pathway Architect [50] (Iobion/Stratagene,
Amsterdam, the Netherlands) for a primary setup, added with more detailed
knowledge from the literature. The genes annotated for mitochondrial proteins
and involvement in mitochondrial development were further curated according
to the MiGene database [51]. A set of genes that appeared to be involved in
amino acid metabolism was further identified by PathwayFinder/Pathway
Miner [52].
PCR procedures
cDNA synthesis was performed using recombinant M-MLV reverse
transcriptase (Sigma-Aldrich, Zwijdrecht, the Netherlands). Real-time quanti-
tative PCR was performed as previously described [12]. Primers (Invitrogen,
Paisly, UK) and fluorogenic probes (Eurogentec, Seraing, Belgium) used in
these studies were described elsewhere (http://www.LabPediatricsrug.nl) or
listed in Supplemental Table 1. All data were subsequently normalized to β-
actin/18S rRNA ratio, which where analyzed in separate runs.Acknowledgments
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